HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis reiterates a Buy rating on Viking Therapeutics (NASDAQ:VKTX) and maintains a $90 price target.
March 08, 2024 | 11:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Viking Therapeutics maintains a Buy rating and a $90 price target from HC Wainwright & Co.
Analyst ratings, especially from reputable firms like HC Wainwright & Co., can significantly influence investor sentiment and stock prices. The reiteration of a Buy rating and a high price target suggests a strong bullish outlook for Viking Therapeutics, likely leading to positive short-term price movement.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100